(Q82448489)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071882%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071882%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

Robert Schmouder

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071882%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Sam Hariry

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071882%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Olivier J David

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071882%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

10 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071882%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Clinical Pharmacology

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071882%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071882%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071882%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

355-362

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071882%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00228-011-1146-9

16 January 2020

exact match

0 references

cites work

Multiple sclerosis--the plaque and its pathogenesis

1 reference

12 December 2020

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

1 reference

12 December 2020

Pulmonary and vascular pharmacology of sphingosine 1-phosphate

1 reference

12 December 2020

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

12 December 2020

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

1 reference

12 December 2020

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

12 December 2020

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

1 reference

12 December 2020

FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs

1 reference

12 December 2020

FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.

1 reference

12 December 2020

Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects

1 reference

12 December 2020

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

1 reference

12 December 2020

FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects

1 reference

12 December 2020

Sphingosine 1-phosphate causes airway hyper-reactivity by rho-mediated myosin phosphatase inactivation

1 reference

12 December 2020

The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I.

1 reference

12 December 2020

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

12 December 2020

Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects

1 reference

12 December 2020

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

1 reference

12 December 2020